Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketoanalogues and Low Protein Diet in CKD
NCT03959228Phase 3Unknown
- Sponsor
- Hospices Civils de Lyon
- Start
- Nov 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Ketosteril in chronic kidney disease (CKD) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Indoxyl Sulfate Plasmatic concentration at 3 months. Status: unknown.
02
Drugs
Ketosteril
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03959228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03959228.